Varying Dialysate Calcium Dosage Not Tied to Differences in All-Cause, Cardiovascular Mortality
By Lori Solomon HealthDay Reporter
FRIDAY, Oct. 18, 2024 -- There are no significant differences in all-cause or cardiovascular mortality with the prescription of dialysate calcium 1.50 versus 1.25 mmol/L for patients undergoing hemodialysis, according to a study published online Oct. 4 in the Clinical Kidney Journal.
Karlien J. ter Meulen, from Maastricht University Medical Centre in the Netherlands, and colleagues investigated the association between dialysate calcium and all-cause, cardiovascular, and sudden cardiac death in hemodialysis patients. The analysis included 12,897 patients with dialysate calcium 1.25 mmol/L and 26,989 patients with dialysate calcium 1.50 mmol/L initiation.
The researchers found that the unadjusted risk for all-cause mortality was higher for dialysate calcium 1.50 mmol/L (hazard ratio [HR], 1.07). When fully adjusting for other confounders, there were no significant differences (HR, 1.05; 95 percent confidence interval [CI], 0.99 to 1.12). Similar results were seen for cardiovascular mortality (HR, 1.03; 95 percent CI, 0.94 to 1.13). For sudden cardiac death, risk was lower for dialysate calcium 1.50 mmol/L (HR, 0.81). With larger serum-to-dialysate calcium gradients, there were significant and positive associations for all outcomes, which were primarily mediated by the serum calcium level.
“This study supports the European Renal Best Practice recommendations that dialysate calcium prescription should be based on consideration of individual patient characteristics,” the authors wrote.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Baxdrostat Reduces Seated Systolic BP in Uncontrolled, Resistant Hypertension
MONDAY, Sept. 8, 2025 -- The addition of baxdrostat, an aldosterone synthase inhibitor, to background therapy yields a significant reduction in seated systolic blood pressure...
Predialysis Nephrology Care Disparities Contribute to Vascular Access
FRIDAY, Sept. 5, 2025 -- System-based disparities in predialysis access to nephrology care contribute to disparities in the likelihood of having a mature, usable arteriovenous...
Mortality Rates From Hypertensive Renal Disease Increased From 1999 to 2023
FRIDAY, Sept. 5, 2025 -- From 1999 to 2023, there was an increase in age-adjusted mortality rates (AAMRs) for hypertensive renal disease, according to a study presented at the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.